DK1368032T3 - Exitatoriske aminosyrereceptorantagonister - Google Patents

Exitatoriske aminosyrereceptorantagonister

Info

Publication number
DK1368032T3
DK1368032T3 DK01274491T DK01274491T DK1368032T3 DK 1368032 T3 DK1368032 T3 DK 1368032T3 DK 01274491 T DK01274491 T DK 01274491T DK 01274491 T DK01274491 T DK 01274491T DK 1368032 T3 DK1368032 T3 DK 1368032T3
Authority
DK
Denmark
Prior art keywords
amino acid
receptor antagonists
acid receptor
excitatory amino
excitatory
Prior art date
Application number
DK01274491T
Other languages
Danish (da)
English (en)
Inventor
Thomas John Bleisch
Perez Jose Antonio Martinez
Paul Leslie Ornstein
Scott Allan May
Andrew Michael Ratz
Thomas Michael Wilson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK1368032T3 publication Critical patent/DK1368032T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK01274491T 2001-01-05 2001-12-19 Exitatoriske aminosyrereceptorantagonister DK1368032T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01500004 2001-01-05
PCT/US2001/045857 WO2003024453A1 (en) 2001-01-05 2001-12-19 Excitatory amino acid receptor antagonists

Publications (1)

Publication Number Publication Date
DK1368032T3 true DK1368032T3 (da) 2008-09-29

Family

ID=8183456

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01274491T DK1368032T3 (da) 2001-01-05 2001-12-19 Exitatoriske aminosyrereceptorantagonister

Country Status (16)

Country Link
EP (2) EP1368032B1 (enExample)
JP (2) JP4132049B2 (enExample)
CN (1) CN100548299C (enExample)
AR (1) AR035219A1 (enExample)
AT (1) ATE397931T1 (enExample)
AU (1) AU2001298028B8 (enExample)
BR (1) BR0116724A (enExample)
CA (1) CA2432464C (enExample)
CY (1) CY1108259T1 (enExample)
DE (1) DE60134427D1 (enExample)
DK (1) DK1368032T3 (enExample)
ES (1) ES2306690T3 (enExample)
MX (1) MXPA03005982A (enExample)
PE (1) PE20020842A1 (enExample)
PT (1) PT1368032E (enExample)
WO (1) WO2003024453A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1511741E (pt) 2002-04-26 2013-02-05 Lilly Co Eli Derivados éster de um ácido deca-hidroisoquinolino-3- carboxílico como analgésicos
MX2022015407A (es) 2020-06-05 2023-05-16 Noema Pharma Ag Metodos de tratamiento del complejo de esclerosis tuberosa.
TWI924682B (zh) * 2020-07-30 2026-05-11 瑞士商諾埃瑪製藥公司 三叉神經痛之治療方法
CN116332807A (zh) * 2023-03-24 2023-06-27 安徽秀朗新材料科技有限公司 一种3-(三氟甲基磺酰基)-2-萘甲酸甲酯的生产工艺

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284957A (en) * 1992-09-03 1994-02-08 Eli Lilly And Company Excitatory amino acid receptor antagonists
US5446051A (en) * 1994-05-31 1995-08-29 Eli Lilly And Company Aryl-spaced decahydroisoquinoline-3-carboxylic acids as excitatory amino acid receptor antagonists
TR199902449T2 (xx) * 1997-04-07 2000-07-21 Eli Lilly And Company Farmakolojik etkin maddeler.
DZ3209A1 (fr) * 1999-07-06 2001-01-11 Lilly Co Eli Antagonistes selectifs du recepteur iGLuR5 utilises dans le traitement de la migraine.
AU2574801A (en) * 1999-12-22 2001-07-03 Eli Lilly And Company Selective iGLUR5 receptor antagonists

Also Published As

Publication number Publication date
PE20020842A1 (es) 2002-09-21
MXPA03005982A (es) 2003-09-10
CN100548299C (zh) 2009-10-14
AU2001298028B2 (en) 2006-07-13
EP1368032B1 (en) 2008-06-11
CA2432464C (en) 2011-07-19
JP4132049B2 (ja) 2008-08-13
EP2166003A1 (en) 2010-03-24
ATE397931T1 (de) 2008-07-15
JP2008179650A (ja) 2008-08-07
WO2003024453A1 (en) 2003-03-27
ES2306690T3 (es) 2008-11-16
CA2432464A1 (en) 2003-03-27
BR0116724A (pt) 2004-01-27
JP2004522804A (ja) 2004-07-29
PT1368032E (pt) 2008-09-04
AU2001298028B8 (en) 2006-08-10
DE60134427D1 (de) 2008-07-24
CN1856308A (zh) 2006-11-01
EP1368032A1 (en) 2003-12-10
AR035219A1 (es) 2004-05-05
CY1108259T1 (el) 2014-02-12

Similar Documents

Publication Publication Date Title
NO20051871D0 (no) Opioid reseptorantagonister
EP1401476A4 (en) IGF-ANTAGONISTS PEPTIDES
DK1446379T3 (da) Arylanilin-beta2-adrenergiske receptoragonister
IS7583A (is) Kalsítóníngen-skyld peptíð viðtaka mótlyf
DE60216229D1 (de) Il-8-rezeptorantagonisten
DK1163239T3 (da) Modificerede aminosyreamider som CGRP-antagonister
NO20034452L (no) Sykdoms-assosiert protein
ATE469875T1 (de) Nk1-antagonisten
BR0207810A (pt) inibidores de deformilase de peptìdeo
ATE374183T1 (de) Nk1-antagonisten
DE60226419D1 (de) Somatostatin-antagonisten
ATE397931T1 (de) Exzitatorische aminosäure-rezeptor-antagonisten
NO20032963D0 (no) Peptidforbindelser
IS6818A (is) Histamín viðtaka mótlyf
NO20032973D0 (no) Eksitatoriske aminosyrereseptorantagonister
ATE370932T1 (de) Ccr-3-rezeptorantagonisten vii
AU2002227020A1 (en) Pyrrolidinylmethyl- and piperidinyl substituted decahydroisoquinolines as excitatory amino acid receptor antagonists
ATE320254T1 (de) Crf receptor antagonisten
HK1060350A (en) Excitatory amino acid receptor antagonists
AU2002228736A1 (en) Pyrrolidinylmethyl substituted decahydroisoquinolines as excitatory amino acid receptor antagonists
NO20053512D0 (no) IL-8-liknende proteiner
NO20052608D0 (no) Midkinlignende protein
DK1302107T3 (da) Spröjteapparat
SE0100442D0 (sv) Sammanfognings - spik
SE0003996D0 (sv) Receptorantagonister